🚀 VC round data is live in beta, check it out!
Gentian Diagnostics Overview
About Gentian Diagnostics
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.
Founded
2001
HQ
Employees
63
Website
Financials (LTM)
EV
$64M
Gentian Diagnostics Financials
Gentian Diagnostics reported last 12-month revenue of $20M and EBITDA of $4M.
In the same LTM period, Gentian Diagnostics generated $12M in gross profit, $4M in EBITDA, and $2M in net income.
Revenue (LTM)
Gentian Diagnostics P&L
In the most recent fiscal year, Gentian Diagnostics reported revenue of $19M and EBITDA of $4M.
Gentian Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $20M | XXX | $19M | XXX | XXX | XXX |
| Gross Profit | $12M | XXX | $10M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $4M | XXX | $4M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $2M | XXX | $1M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 7% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Gentian Diagnostics Stock Performance
Gentian Diagnostics has current market cap of $73M, and enterprise value of $64M.
Market Cap Evolution
Gentian Diagnostics' stock price is $4.73.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $64M | $73M | -0.1% | XXX | XXX | XXX | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGentian Diagnostics Valuation Multiples
Gentian Diagnostics trades at 3.2x EV/Revenue multiple, and 14.6x EV/EBITDA.
EV / Revenue (LTM)
Gentian Diagnostics Financial Valuation Multiples
As of April 20, 2026, Gentian Diagnostics has market cap of $73M and EV of $64M.
Equity research analysts estimate Gentian Diagnostics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gentian Diagnostics has a P/E ratio of 32.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $73M | XXX | $73M | XXX | XXX | XXX |
| EV (current) | $64M | XXX | $64M | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 14.6x | XXX | 17.0x | XXX | XXX | XXX |
| EV/EBIT | 19.8x | XXX | 23.6x | XXX | XXX | XXX |
| EV/Gross Profit | 5.5x | XXX | 6.1x | XXX | XXX | XXX |
| P/E | 32.7x | XXX | 51.7x | XXX | XXX | XXX |
| EV/FCF | 31.3x | XXX | 18.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Gentian Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Gentian Diagnostics Margins & Growth Rates
Gentian Diagnostics' revenue in the last 12 month grew by 21%.
Gentian Diagnostics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Gentian Diagnostics' rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gentian Diagnostics' rule of X is 82% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Gentian Diagnostics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 56% | XXX | 61% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 82% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Gentian Diagnostics Public Comps
See public comps and valuation multiples for other Laboratory Services and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Gentian Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aiforia | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioporto | XXX | XXX | XXX | XXX | XXX | XXX |
| FluoGuide | XXX | XXX | XXX | XXX | XXX | XXX |
| Exagen | XXX | XXX | XXX | XXX | XXX | XXX |
| Chandan Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gentian Diagnostics M&A Activity
Gentian Diagnostics acquired XXX companies to date.
Last acquisition by Gentian Diagnostics was on XXXXXXXX, XXXXX. Gentian Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Gentian Diagnostics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGentian Diagnostics Investment Activity
Gentian Diagnostics invested in XXX companies to date.
Gentian Diagnostics made its latest investment on XXXXXXXX, XXXXX. Gentian Diagnostics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Gentian Diagnostics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Gentian Diagnostics
| When was Gentian Diagnostics founded? | Gentian Diagnostics was founded in 2001. |
| Where is Gentian Diagnostics headquartered? | Gentian Diagnostics is headquartered in Norway. |
| How many employees does Gentian Diagnostics have? | As of today, Gentian Diagnostics has over 63 employees. |
| Is Gentian Diagnostics publicly listed? | Yes, Gentian Diagnostics is a public company listed on Oslo Børs. |
| What is the stock symbol of Gentian Diagnostics? | Gentian Diagnostics trades under GENT ticker. |
| When did Gentian Diagnostics go public? | Gentian Diagnostics went public in 2016. |
| Who are competitors of Gentian Diagnostics? | Gentian Diagnostics main competitors are Aiforia, Bioporto, FluoGuide, Exagen. |
| What is the current market cap of Gentian Diagnostics? | Gentian Diagnostics' current market cap is $73M. |
| What is the current revenue of Gentian Diagnostics? | Gentian Diagnostics' last 12 months revenue is $20M. |
| What is the current revenue growth of Gentian Diagnostics? | Gentian Diagnostics revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Gentian Diagnostics? | Current revenue multiple of Gentian Diagnostics is 3.2x. |
| Is Gentian Diagnostics profitable? | Yes, Gentian Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gentian Diagnostics? | Gentian Diagnostics' last 12 months EBITDA is $4M. |
| What is Gentian Diagnostics' EBITDA margin? | Gentian Diagnostics' last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Gentian Diagnostics? | Current EBITDA multiple of Gentian Diagnostics is 14.6x. |
| What is the current FCF of Gentian Diagnostics? | Gentian Diagnostics' last 12 months FCF is $2M. |
| What is Gentian Diagnostics' FCF margin? | Gentian Diagnostics' last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Gentian Diagnostics? | Current FCF multiple of Gentian Diagnostics is 31.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.